CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.
UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.
Source: finance.yahoo.com
Related posts:
Leonardo DiCaprio-Backed Polestar Valued at $20 Billion in SPAC Deal
The US is the world’s biggest oil producer — so why do we still need to import crude and ask countri...
Mortgage rates just took the biggest plunge since 1981 — but analysts say the market is ‘not out of ...
Billionaire Ken Griffin Goes Bargain Hunting: 3 Stocks He Just Bought
Jim Cramer Says Dow Jones Likely to Continue Outperforming; Here Are 3 Dow Stocks That Analysts Like